Sept 28 (Reuters) – Merck on Monday agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug, making it the latest US drugmaker to license China-developed medicines. Chinese biotechs often retain domestic rights and license their drugs overseas in exchange for upfront and milestone payments as well […]
Health
Factbox-US drugmakers turn to China for licensing deals
Audio By Carbonatix
Sept 28 (Reuters) – Merck on Monday agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug, making it the latest US drugmaker to license China-developed medicines.
Chinese biotechs often retain domestic rights and license their drugs overseas in exchange for upfront and milestone payments as well as royalties.
Some major deals are listed below:
Date US Chinese Deal Assets/pro Upfro Potentia
company company type grams nt l value
value
Septem Merck SciBrunc Licens SPR2015, $400 Up to
ber h ing experiment milli $2.13
2026 Therapeu al cancer on billion
tics drug
May Pfizer Innovent Licens 12 $650 Up to
2026 Biologic ing early-stag milli $10.5
s e oncology on billion
programs
May Bristol Jiangsu Licens 13 $600 Up to
2026 Myers Hengrui ing early-stag milli $15.2
Squibb Pharmace e programs on billion
uticals in
oncology,
hematology
and
immunology
Februa Eli Innovent Licens Experiment $350 Up to
ry Lilly Biologic ing al cancer milli $8.85
2026 s and on billion
immunology
drugs
Januar AbbVie RemeGen Licens RC148, $650 Up to
y 2026 ing experiment milli $5.6
al cancer on billion
drug
June Regener Hansoh Licens HS-20094/o $80 Up to
2025 on Pharma ing latorepati milli $2.01
Pharmac de, on billion
eutical GLP-1/GIP
s obesity
drug
May Pfizer 3SBio Licens SSGJ-707, $1.25 Up to
2025 ing experiment billi $6.05
al cancer on billion,
drug not
includin
g
Pfizer’s
$100
million
equity
investme
nt
Decemb Merck Hansoh Licens HS-10535, $112 Up to $2
er Pharma ing oral milli billion
2024 weight-los on
s pill
Novemb Merck LaNova Licens LM-299, $588 Up to
er Medicine ing experiment milli $3.3
2024 s al cancer on billion
drug
June AbbVie FutureGe Licens FG-M701, $150 Up to
2024 n ing experiment milli $1.71
Biopharm al on billion
aceutica inflammato
l ry bowel
disease
drug
Decemb Bristol Sichuan Licens BL-B01D1, $800 Up to
er Myers Biokin ing experiment milli $8.4
2023 Squibb Pharmace al on billion
utical antibody
/SystImm cancer
une drug
Decemb Summit Akeso Licens Ivonescima $500 Up to $5
er Therape ing b, milli billion
2022 utics experiment on
al cancer
therapy
(Reporting by Siddhi Mahatole and Kunal Das in Bengaluru; Editing by Sahal Muhammed)